ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jul 1, 2017
The Financially-Healthiest Dividend Payers Yielding Over 2%
We multiply each firm’s dividend yield by its Dividend Cushion ratio to get this coveted list of the financially-healthiest dividend payers yielding over 2%. Use the download in this article to develop this screen.
Jun 28, 2017
Incyte, Examining Epacadosat's Recent Data
Image shown: Incyte's stock price performance since the beginning of 2014.The need for innovative advances in oncology remains unmet in spite of the entrance of next-generation treatments. We will examine the recent data release from Incyte pertaining to its novel treatment Epacadosat. Incyte hopes it will boost response rates which will greatly expand the number of patients that can be effectively treated. Let’s examine the details of the data release.
Jun 27, 2017
Do You Know What You Don't Know?
Find out what you may have missed with a short excerpt by speaker Brian Nelson from part III of Valuentum's four-part investment education workshop. You may be surprised!
Jun 26, 2017
Random Musings: Retail, REITs, BlackBerry, and More
Image shown: Best Buy's resiliency in the face of competition from Amazon. Let’s cover some recent news.
Jun 20, 2017
Best Ideas, Dividend Growth Newsletter Alerts and More
Image shown: The stock price performance of Boeing. Let’s take a look at recent news from newsletter portfolio holdings. We’re also parting with a “trade” we never should have made in the first place, and we’re letting go of one of our favorite restaurants in light of deteriorating technicals. This and more...
Jun 16, 2017
Amazon To Buy Whole Foods: Not Creative Destruction, Just Destruction
Image Source: Mike Mozart. Amazon announced plans to buy Whole Foods. We’re viewing the news as affirmation of our decision to stay largely away from retail exposure in the newsletter portfolios. We think a bidding war for Whole Foods is possible, mostly to keep it and its real estate out of the hands of Amazon, potentially setting up for a true “winner’s curse” scenario. The winner will overpay.
Jun 10, 2017
Glossary of Valuentum Terms
Image Source: Courtney Collison. We define the sections and proprietary metrics found in Valuentum's stock reports.
Jun 8, 2017
Verint’s Cyber Intelligence Division Impresses
Image Source: Blogtrepreneur. One of the latest additions to the Best Ideas Newsletter portfolio experienced strong top-line growth in both of its operating segments during the first quarter, and we continue to like the company’s exposure to the cyber intelligence arena.
May 31, 2017
Nevro: An Exciting But Risky Medtech Idea in the Early Stages of Its Growth
Image Source: Nevro. Innovation continues to thrive in the medical field. The rapid aging of the industrialized world’s population bodes well for rising demand. Let’s look at a promising med tech idea, which we believe offers explosive growth in the field of Neuromodulation. It's a risky one though.
May 26, 2017
Alexion’s Executive Departures and an Update from Regeneron Pharma
Image shown above: Performance of Regeneron since the summer of 2013.An executive scandal continues to mar the performance of Alexion Pharmaceuticals. The CFO has resigned his position effective the end of August, but there is more to this story. Let’s also talk Regeneron.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.